Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer

Markus F. Renschler; Alan R. Yuen; Timothy J. Panella; Thomas Jeffery Wieman M.D.; Shona Dougherty; Laura Esserman; Masoud Panjehpour; Scott W. Taber M.D.; Victor H. Fingar; Elizabeth Lowe; Julie S. Engel; Bert Lum; Kathryn W. Woodburn; Wai-Fung Cheong; Richard A. Miller

doi:10.1117/12.308147

19 May 1998 Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer

Markus F. Renschler, Alan R. Yuen, Timothy J. Panella, Thomas Jeffery Wieman M.D., Shona Dougherty, Laura Esserman, Masoud Panjehpour, Scott W. Taber M.D., Victor H. Fingar, Elizabeth Lowe, Julie S. Engel, Bert Lum, Kathryn W. Woodburn, Wai-Fung Cheong, Richard A. Miller

Author Affiliations +

Proceedings Volume 3247, Optical Methods for Tumor Treatment and Detections: Mechanisms and Techniques in Photodynamic Therapy VII; (1998) https://doi.org/10.1117/12.308147
Event: BiOS '98 International Biomedical Optics Symposium, 1998, San Jose, CA, United States

Abstract

Photodynamic therapy (PDT) of locally recurrent breast cancer has been limited to treatment of small lesions because of non- selective necrosis of adjacent normal tissues in the treatment field. Lutetium Texaphyrin (PCI-0123, Lu-Tex) is a photosensitizer with improved tumor localization that is activated by 732 nm light, which can penetrate through larger tumors. We have evaluated Lu-Tex in a Phase I trial and in an ongoing Phase II trial in women with locally recurrent breast cancer with large tumors who have failed radiation therapy. Patients received Lu-Tex intravenously by rapid infusion 3 hours before illumination of cutaneous or subcutaneous lesions. In Phase I, Lu-Tex doses were escalated from 0.6 to 7.2 mg/kg in 7 cohorts. Sixteen patients with locally recurrent breast cancer lesions were treated. Dose limiting toxicities above 5.5 mg/kg were pain in the treatment field during therapy, and dysesthesias in light exposed areas. No necrosis of normal tissues in the treated field was noticed. Responses were observed in 60% of evaluable patients [n equals 15, 27% complete remission (CR), 33% partial remission (PR)], with 63% of lesions responding (n equals 73: 45% CR, 18% PR). In Phase II, 25 patients have been studied to date, receiving two treatments ranging from 1.0 to 3.0 mg/kg at a 21 day interval. Treatment fields up to 480 cm² in size were treated successfully and activity has been observed. Patients have experienced pain at the treatment site but no tissue necrosis. These studies demonstrate the feasibility of Lu-Tex PDT to large chest wall areas in women who have failed radiation therapy for the treatment of locally recurrent breast cancer. Treatment conditions are currently being optimized in the ongoing Phase II trials.

Citation Download Citation

Markus F. Renschler, Alan R. Yuen, Timothy J. Panella, Thomas Jeffery Wieman M.D., Shona Dougherty, Laura Esserman, Masoud Panjehpour, Scott W. Taber M.D., Victor H. Fingar, Elizabeth Lowe, Julie S. Engel, Bert Lum, Kathryn W. Woodburn, Wai-Fung Cheong, and Richard A. Miller "Photodynamic therapy trials with lutetium texaphyrin (Lu-Tex) in patients with locally recurrent breast cancer", Proc. SPIE 3247, Optical Methods for Tumor Treatment and Detections: Mechanisms and Techniques in Photodynamic Therapy VII, (19 May 1998); https://doi.org/10.1117/12.308147

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available